3 citations,
March 2021 in “JAAD case reports” Switching from adalimumab to ixekizumab improved a patient's psoriasis and reversed hair whitening.
1 citations,
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.
August 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ixekizumab may be an effective first treatment for a rare skin condition causing hair loss.
April 2023 in “Journal of dermatological treatment” Ixekizumab successfully treated a rare hair loss condition, leading to complete hair regrowth.
April 2016 in “Journal of The American Academy of Dermatology” Ixekizumab is effective and safe for patients who did not improve with etanercept treatment for psoriasis.
21 citations,
July 2022 in “Orphanet journal of rare diseases” New treatments for ichthyosis, like protein replacement and gene therapy, show promise and may become standard care.
4 citations,
November 2020 in “Psoriasis : Targets and Therapy” The document concludes that proper treatment and management of plaque psoriasis in adolescents can improve their quality of life.
3 citations,
May 2020 in “JAAD Case Reports” Two patients with psoriasis grew extra hair after using certain psoriasis medications.
1 citations,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
January 2020 in “Journal of The European Academy of Dermatology and Venereology” In 2019, dermatology and venereology improved skin cancer imaging, advanced in treating skin conditions like psoriasis, and explored the skin microbiome's role in diseases.
April 2016 in “Journal of The American Academy of Dermatology” Lichen planus may be associated with a higher risk of metabolic syndrome.
278 citations,
March 2013 in “Gut” Anti-IL-12/IL-23 antibody therapy effectively treats psoriasiform skin lesions in IBD patients.
144 citations,
November 2020 in “Frontiers in immunology” Targeting the IL-23/IL-17 pathway effectively treats several inflammatory skin diseases.
101 citations,
July 2020 in “Dermatologic therapy” COVID-19 can cause skin issues like rashes and "COVID toes," and people with skin conditions should adjust their treatments if they get the virus.
59 citations,
June 2022 in “Frontiers in medicine” There are still challenges in diagnosing and treating chronic skin diseases, but there is hope for future improvements.
49 citations,
January 2018 in “Immunology” Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.
36 citations,
December 2015 in “Drugs” New treatments for a chronic skin condition show promise, but individualized plans are crucial due to varying responses.
23 citations,
July 2021 in “Advances in Therapy” Most people with Alopecia Areata don't get treatment within a year; it's costly and often comes with other health issues.
23 citations,
January 2020 in “Central-European Journal of Immunology/Central European Journal of Immunology” Alopecia areata, a type of hair loss, is likely an autoimmune disease with a genetic link, but its exact cause is still unknown.
16 citations,
September 2020 in “British journal of dermatology/British journal of dermatology, Supplement” The article suggests that targeting specific immune pathways could help control and treat the skin disease hidradenitis suppurativa.
16 citations,
May 2019 in “International Journal of Women's Dermatology” The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.
4 citations,
January 2022 in “Current pharmaceutical design” Microsponges delivery system is a safe, versatile method for controlled drug release in various treatments.
New treatments for vitiligo may focus on protecting melanocyte stem cells from stress and targeting specific pathways involved in the condition.
1 citations,
January 2017 in “Expert opinion on orphan drugs” Adalimumab is the most effective treatment for severe hidradenitis suppurativa, but more research is needed to improve treatment options.
February 2024 in “Curēus” Secukinumab can cause hair loss, which may improve after stopping the medication.
November 2023 in “Frontiers in pharmacology” Drug repositioning offers hope for new, affordable treatments for a genetic skin disorder called ARCI.
February 2023 in “Research Square (Research Square)” Blocking IL-17 can reduce skin inflammation in a mouse model of pityriasis rubra pilaris.
The document is a detailed guide on skin conditions and treatments for dermatologists.